UroGen Pharma Ltd (NASDAQ:URGN) price on Friday, February 28, rose 1.83% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $9.46.
A look at the stock’s price movement, the close in the last trading session was $9.29. Turning to its 52-week performance, $20.70 and $9.21 were the 52-week high and 52-week low respectively. Overall, URGN moved -14.08% over the past month.
UroGen Pharma Ltd’s market cap currently stands at around $399.20 million, with investors looking forward to this quarter’s earnings report slated for in April.
Analysts have a consensus estimate of 25.25M for the company’s revenue for the quarter, with a low and high estimate of 22M and 27.6M respectively. The average forecast suggests up to a 7.30% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 91M, representing a 10.01% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that URGN is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
7 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 5 recommend URGN as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
URGN’s current price about -9.48% and -10.60% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 35.88, while 7-day volatility ratio is 5.33% and 4.98% in the 30-day chart. Further, UroGen Pharma Ltd (URGN) has a beta value of 1.14, and an average true range (ATR) of 0.51. Analysts have given the company’s stock an average 52-week price target of $25, forecast between a low of $25 and high of $25. Looking at the price targets, the low is -164.27% off current price level while to achieve the yearly target high, price needs to move -164.27%. Nonetheless, investors will most likely welcome a -164.27% jump to $25 which is the analysts’ median price.
If we refocus on UroGen Pharma Ltd (NASDAQ:URGN), historical trading data shows that trading volumes averaged 372.70K over the past 3 months. The company’s latest data on shares outstanding shows there are 42.19 million shares.
The 17.09% of UroGen Pharma Ltd’s shares are in the hands of company insiders while institutional holders own 87.89% of the company’s shares. Current price change has pushed the stock -11.17% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the URGN stock continues to rise going into the next quarter.
